Canis ISSN: 2398-2942

Esmolol

Introduction

Class of drug

  • Ultra short-acting beta blocker.

Uses

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Indications

  • Treatment of supraventicular tachycardia:

Administration

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Pharmocokinetics

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Precautions

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Interactions

with other drugs



Sympathomimetics
Anaesthetic agents, phenothiazines, antihypertensives, diazepam, diuretics and antiarrhythmics
  • Enhance hypotensive effect.
Calcium channel blockers
  • Diltiazem Diltiazem and verapamil Verapamil increase risk of bradycardia, severe hypotension, heart failure and AV block.
Digoxin
  • Bradycardia increased by concurrent administration.
Thyroid hormones
  • Enhance metabolism of esmolol thus reduce effect.
  • Dose of esmolol should be decreased when initiating carbimazole Carbimazole therapy.
Cimetidine
  • May decrease metabolism of esmolol.
Muscle relaxants
  • Esmolol enhances effects of suxamethonium Suxamethonium , tubocurarine.
Phenobarbitone and phenytoin
  • May increase rate of metabolism of esmolol by hepatic enzyme induction.
lignocaine
  • Reduces lignocaine Lidocaine clearance therefore increases risk of lignocaine toxicity.
Theophylline
  • May block bronchodilatory effects of theophylline Theophylline.

Adverse Reactions

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Further Reading

Publications

Other sources of information

  • Based onSmall Animal Formulary. Tennant, Bryn (1999) 3rd edn. Cheltenham: BSAVA.

ADDED